Related Experiment Video

Updated: May 23, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

A Novel Combination Therapy Approach Targeting STAT3 and Autophagy in Glioblastoma

Sujoy Bhattacharya1, Lawrence M Pfeffer2, Edward Chaum1

  • 1Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN.

Autophagy Reports
|May 21, 2025
PubMed

Insights

Targeting signal transducer and activator of transcription 3 (STAT3) and autophagy pathways may overcome glioblastoma (GBM) resistance to therapy. Dual inhibition strategies show promise for reducing GBM growth and chemoresistance.

Area of Science:

  • Neuro-oncology
  • Cancer biology
  • Molecular therapy

Background:

  • Glioblastoma (GBM) exhibits resistance to standard treatments, leading to recurrence.
  • GBM progression is critically dependent on signal transducer and activator of transcription 3 (STAT3) signaling.
  • STAT3 regulates autophagy, a cellular process implicated in GBM pathobiology.

Purpose of the Study:

  • To investigate the role of autophagy modulation in glioblastoma tumorigenesis.
  • To explore the potential of dual inhibition of STAT3 and autophagy-related pathways as a therapeutic strategy for GBM.

Main Methods:

  • Analysis of STAT3 and autophagy pathway interactions in GBM.
  • Evaluation of therapeutic efficacy of combined STAT3 inhibition with MTOR or ULK1 inhibition.

Main Results:

  • STAT3 inhibition effectively blocks GBM tumor growth.
  • Modulation of autophagy can reduce GBM tumorigenesis and chemoresistance.
  • Dual inhibition of STAT3 and MTOR, or STAT3 and ULK1, demonstrates therapeutic potential.

Conclusions:

  • Targeting STAT3 and autophagy pathways offers a novel therapeutic approach for GBM.
  • Combined inhibition strategies may overcome treatment resistance and improve patient outcomes in glioblastoma.
Keywords:
AMPKαLC3-I/LC3-IIMTORC1RAD001 (everolimus)ULK1apoptosiscaspase 3cathepsin D

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.0K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K